Literature DB >> 29205910

Role of intravenous immunoglobulin in the treatment of Kawasaki disease.

Mindy S Lo1,2, Jane W Newburger2,3.   

Abstract

Intravenous immunoglobulin (IVIg) is a purified plasma product that is used for many immune-deficient conditions and autoimmune conditions. Use of IVIg for treatment for Kawasaki disease (KD) is critical for control of inflammation. The American Heart Association (AHA) recommends a single infusion of 2 g/kg preferably given during the first 10 days of illness. In this review, we have discussed the possible mechanisms of action of IVIg in KD and its clinical usage in this condition.
© 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Kawasaki disease; intravenous immunoglobulin

Mesh：

Substances：

Year:  2017        PMID： 29205910     DOI： 10.1111/1756-185X.13220

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN： 1756-1841            Impact factor:   2.454


  21 in total

Review 1.  Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge.

Authors:  Gladys El-Chaar
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-12       Impact factor: 0.885

Review 2.  Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.

Authors:  Filippo Milano; Joshua A Hill; Lorenzo Iovino; Laurel A Thur; Sacha Gnjatic; Aude Chapuis
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

3.  Bioinformatics identification of hub genes and signaling pathways regulated by intravenous immunoglobulin treatment in acute Kawasaki disease.

Authors:  Hongbiao Huang; Lei Xu; Yueyue Ding; Jie Qin; Chengcheng Huang; Xuan Li; Yunjia Tang; Guanghui Qian; Haitao Lv
Journal:  Exp Ther Med       Date:  2021-05-19       Impact factor: 2.447

Review 4.  Cytokine cascade in Kawasaki disease versus Kawasaki-like syndrome.

Authors:  M A Bordea; C Costache; A Grama; A I Florian; I Lupan; G Samasca; D Deleanu; P Makovicky; P Makovicky; K Rimarova
Journal:  Physiol Res       Date:  2022-01-19       Impact factor: 1.881

5.  Neurological involvement in Kawasaki disease: a retrospective study.

Authors:  Xiaoliang Liu; Kaiyu Zhou; Yimin Hua; Mei Wu; Lei Liu; Shuran Shao; Chuan Wang
Journal:  Pediatr Rheumatol Online J       Date:  2020-07-14       Impact factor: 3.054

6.  Structure equation model and neural network analyses to predict coronary artery lesions in Kawasaki disease: a single-centre retrospective study.

Authors:  Junji Azuma; Takehisa Yamamoto; Motoaki Nitta; Yasuhiro Hasegawa; Eri Kijima; Tsunesuke Shimotsuji; Yoshimi Mizoguchi
Journal:  Sci Rep       Date:  2020-07-17       Impact factor: 4.379

7.  Distinct variations of antibody secreting cells and memory B cells during the course of Kawasaki disease.

Authors:  Meng Xu; Yanfang Jiang; Jinghua Wang; Jinxiang Liu; Congcong Liu; Deying Liu; Sirui Yang
Journal:  BMC Immunol       Date:  2019-06-03       Impact factor: 3.615

8.  Observation on the clinical effect of high-dose Intravenous Immunoglobulin combined with low-dose prednisone acetate in the treatment of patients with Kawasaki Disease.

Authors:  Hao Zhang; Mei-Ying Wang; Yong-Nan Teng; Xiao-Dan Wang; Hai-Tao Cao
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

9.  A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?

Authors:  Wei Li; Xiufang He; Li Zhang; Zhouping Wang; Yanfei Wang; Huimei Lin; Jia Yuan; Xiaofei Xie; Youzhen Qin; Ping Huang
Journal:  Cardiovasc Ther       Date:  2021-06-18       Impact factor: 3.023

10.  Elevated Levels of Pentraxin 3 Correlate With Neutrophilia and Coronary Artery Dilation During Acute Kawasaki Disease.

Authors:  Lauren L Ching; Vivek R Nerurkar; Eunjung Lim; Ralph V Shohet; Marian E Melish; Andras Bratincsak
Journal:  Front Pediatr       Date:  2020-06-25       Impact factor: 3.418
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.